2. ¹è°æ: »ý¸í°øÇп¡¼ÀÇ Çõ½Å°ú ±× Çؼ®
2.1 »ý¸í°øÇÐ Çõ½ÅÀÇ ÁÖ¿ä ³»¿ë
»ý¸í°øÇÐÀ» »ý¹°Ã¼¸¦ ÀÌ¿ëÇÏ¿© À¯¿ëÇÑ ¹°ÁúÀ» »ý»êÇÏ´Â ±â¼ú·Î Á¤ÀÇÇÑ´Ù¸é Àηù°¡ »§À» ±Á°í Æ÷µµÁÖ¸¦ ¸¸µé±â À§ÇØ ¹ßÈ¿±â¼úÀ» ÀÌ¿ëÇÑ ¶§ºÎÅÍ »ý¸í°øÇÐÀº ¹ßÀüÇØ¿Ô´Ù°í º¼ ¼ö ÀÖ´Ù. ±×·¯³ª Çö´ëÀÇ »ý¹°»ê¾÷À» °¡´ÉÄÉ ÇÑ °è±â·Î ÇÐÀÚµéÀÌ °øÅëÀûÀ¸·Î ÁöÀûÇÏ´Â °ÍÀº 1970³â´ë¿¡ ÀÌ·ç¾îÁø µÎ °¡Áö Áß¿äÇÑ Çõ½ÅÀÌ´Ù. ±× Çϳª´Â 1973³â Herbert Boyer¿Í Stanley CohenBoyer´Â Stanford UniversityÀÇ ±³¼ö¿´°í CohenÀº University of California, San FranciscoÀÇ ±³¼ö¿´´Ù. ÀÌ Áß Boyer´Â 1976³â¿¡ º¥Ã³Ä³ÇÇÅи®½ºÆ®ÀÎ Robert Swanson°ú ÃÖÃÊÀÇ Àü¹® »ý¸í°øÇÐ ±â¾÷ÀÎ GenentechÀ» °øµ¿ â¾÷ÇÑ´Ù. ¿ø·¡ Boyer´Â â¾÷ÇÒ »ý°¢ÀÌ ¾ø¾úÀ¸³ª, À̵éÀÌ °³¹ßÇÑ À¯ÀüÀÚ ÀçÁ¶ÇÕ ±â¼úÀÇ »ó¾÷Àû °¡´É¼ºÀ» °£ÆÄÇÑ SwansonÀÌ Boyer¸¦ ¼³µæÇÏ¿© â¾÷ÀÌ ÀÌ·ç¾îÁ³´Ù. ÀÌ ÀÏÈ´Â »ý¸í°øÇÐÀÇ »ó¾÷È¿¡¼ ¹Ì±¹ º¥Ã³Ä³ÇÇÅи®½ºÆ®µéÀÇ ¿ªÇÒÀÌ Áß¿äÇßÀ½À» º¸¿©ÁÖ´Â ´ëÇ¥Àû ÀÏÈ·Î ²ÅÈù´Ù. ÇÑÆí, ÀÌ È¸»ç´Â 1982³â¿¡ ÃÖÃÊÀÇ »ý¸í°øÇÐ ÀǾàÇ°ÀÎ ÀμºÀåÈ£¸£¸ó (human growth hormone)À» »ý»êÇÏ¿© Å©°Ô ¼º°ø½ÃÅ´À¸·Î½á Á¦¾à¾÷°è, ÅõÀÚ¡¦(»ý·«)
|
erson et. al., 1999: 286).Henderson et. al. (1999)´Â Grabowski & VernonÀÇ 1994³â ¿¬±¸¸¦ ÀοëÇÏ¿© 1991³â ÇöÀç 100°³ ÀÌ»óÀÇ »ý¸í°øÇÐ ½Å¾àÀÌ ÀÓ»ó ´Ü°è¿¡ ÀÖ°í, 21°³ÀÇ »ý¸í°øÇÐ ½Å¾àÀÌ FDA¿¡ Á¦ÃâµÈ »óŶó°í Çß´Ù. Pisano (1991)´Â ¹Ì±¹ÀÇȸ ±â¼úÆò°¡±¹ (Office of Technology Assessment)ÀÇ ÀڷḦ ÀοëÇÏ¿© 1988³â ÇöÀç 400°³ÀÇ »ý¸í°øÇÐ ½Å¾àÀÌ ÀÓ»ó ´Ü°è³ª ÀüÀÓ»ó ´Ü°è¿¡ ÀÖ°í, 1989³â ¸» ÇöÀç 8°³ÀÇ »ý¸í°øÇÐ ½Å¾àÀÌ FDA¿¡ ½ÂÀÎ ½ÅûµÇ¾î ÀÖÀ¸¸ç, 1990³â ¸»±îÁö ¶Ç ´Ù¸¥ 14°³ÀÇ »ý¸í°øÇÐ ½Å¾àÀÌ FDA¿¡ Á¦ÃâµÉ ¿¹Á¤À̶ó°í Çß´Ù. Henderson et. al. (1999), p. 293; Pisano (1991), p. 239.
Àü¹® »ý¸í°øÇÐ ±â¾÷µé¿¡ ÀÇÇØ °³¹ßµÈ ´Ü¹éÁú ½Å¾àÀº Å©°Ô µÎ Á¾·ù·Î ³ª´¶´Ù. ÇÑ Á¾·ù´Â ´Ù¸¥ °úÁ¤À» ÅëÇØ »ý»êµÇ¾î ÀÌ¹Ì ½ÃÆÇ ÁßÀ̾ú´ø ¾àÇ°µé (´ç´¢º´ Ä¡·áÁ¦ insulin, ÀμºÀåÈ£¸£¸ó µî)Àε¥, »ý¸í°øÇÐ ±â¾÷µéÀº À¯ÀüÀÚÀçÁ¶ÇÕ ±â¼úÀ» ÀÌ¿ëÇÏ¿© À̸¦ ´ë±Ô¸ð·Î »ý»êÇϴµ¥ ¼º°øÇß´Ù.
ìíÌè¹ÙÀÌ¿ÀÅ×Å© Æí (1991), ¡¸»ý¸í°øÇпë¾îÇؼ³Áý 2000¡¹, ìíÜâÌèðãæÚ¤ (±¹¿ªº»: ¿ë±ºÈ£ ¿Ü ¿ª, 1994, µµ¼ÃâÆÇ ÇѸ²¿ø). Arora, A. and A. Gambardella (1990), ¡°Complementarity and External Linkages: The Strategies of The Large Firms in Biotechnology¡±, The Journal Of Industrial Economics, Vol. 38, pp. 361-379. ______ (1994), ¡°Evaluating Technological Information and Utilizing It: Scientific Knowledge, Technological Capability, and External Linkages in Biotechnology¡±, Journal Of Economic Behavior & Organization, Vol. 24, pp. 91-114. Dodgson, M. (1991), ¡°Strategic Alignment and Organizational Options in Biotechnology Firms¡±, Technology Analysis & Strategic Management, Vol. 3, pp. 115-125. Henderson, R., L. Orsenigo, G. P. Pisano (1999), ¡°The Pharmaceutical Industry and the Revolution in Molecular Biology: Interactions among Scientific, Institutional, and Organizational Change¡±, in David C. M. and Richard R. N. (eds.), Sources of Industrial Leadership: Studies of Seven Industries, Cambridge: Cambridge University Press. Pisano, G. P. (1991), ¡°The Governance of Innovation: Vertical Integration and Collaborative Arrangements in the Biotechnology Industry¡±, Research Policy, Vol. 20, pp. 237-249. Prevezer, M. and S. Toker (1996), ¡°The Degree of Integration in Strategic Aalliances in Biotechnology¡±, Technology Analysis & Strategic Management, Vol. 8, pp. 117-133. Schumpeter, J. (1934), The Theory of Economic Development, Cambridge, MA: Harvard University Press. Shan, W. G. Walker, B. Kogut (1994), ¡°Interfirm Cooperation and Startup Innovation in the Biotechnology Industry¡±, Strategic Management Journal, Vol. 15, pp. 387-394. Senker, J. (1996), ¡°National Systems of Innovation, Organizational Learning and Industrial Biotechnology¡±, Technovation, Vol. 16, pp. 219-229. Senker, J. and M. Sharp (1997), ¡°Organizational Learning in Cooperative Alliances: Some Case Studies in Biotechnology¡±, Technology Analysis & Strategic Management, Vol. 9, pp. 35-51. Tapon, F. and M. Thong (1999), ¡°Research Collaborations by Multi- national Research Oriented Pharmaceutical Firms: 1988-1997¡±, R&D Management, Vol. 29, pp. 219-231. Tushman, M. and P. Anderson (1986), ¡°Technological Discontinuities and Organizational Environment¡±, Administrative Science Quarterly, Vol. 31, pp. 439-456. Utterback, J. M. (1994), Mastering the Dynamics of Innovation, Boston: Harvard Business School Press (±¹¿ª: 「±â¼úº¯È¿Í Çõ½ÅÀü·«」, ±èÀμö, ±è¿µ¹è, ¼ÀÇÈ£ °ø¿ª, 1997, °æ¹®»ç) Whittaker, E. and D. J. Bower (1994), ¡°A Shift to External Alliances for Product Development in the Pharmaceutical Industry¡±, R&D Management, Vol. 24, pp. 249-260. Zucker, L. G. and M. R. Darby (1997), ¡°Present at the Biotechnological Revolution: Transformation of Technological Identity for a Large Incumbent Pharmaceutical Firm¡±, Research Policy, Vol. 26, pp. 429-446.
|